MACE, VTE Risks Not Increased With JAK inhibitors: Study

In studies with an average follow-up of 16 weeks, there was no significant increase in MACE or VTE rates in people with dermatoses treated with JAK-STAT inhibitors.

Related Keywords

Ireland ,Washington ,United States ,Randwick ,New South Wales ,Australia ,Adam Friedman ,Eli Lily ,Drug Administration ,University Of New South Wales ,George Washington University ,Pfizer ,Patrick Ireland ,Dermatological Conditions ,Thromboembolism ,Cv Risk ,Cardiovascular Risk ,V Risk Factors ,Cardiovascular Risk Factors ,Cardiovascular Risk Management ,Stroke Cerebrovascular Accident Cva ,Dermatoses ,Skin Disorders ,Skin Diseases ,Meta Analysis ,Psoriasis ,Pulmonary Embolism Pe Embolus ,Dermatitis ,Venous Thromboembolism ,